MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/pai.13709

Медицинская библиотека · Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021

Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network.

Chiang Chen-Yuan, Ellwood Philippa, Ellwood Eamon, García-Marcos Luis, Masekela Refiloe, Asher Innes, Badellino Héctor, Sanz Alberto Bercedo, Douros Konstantinos, El Sony Asma, Diaz Carlos González, Rodríguez Ms Albi, Moreno-Salvador Ana, Pérez-Martini Luis F, Filho Nelson Rosário, Shpakou Andrei, Sulaimanov Shairbek, Tavakol Marzieh, Valverde-Molina José, Yousef Abdullah A, Pearce Neil, GAN COVID Study Group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Clinical presentations of coronavirus disease 2019 (COVID-19) among children with asthma have rarely been investigated. This study aimed to assess clinical manifestations and outcome of COVID-19 among children with asthma, and whether the use of asthma medications was associated with outcomes of interest.

METHODS

The Global Asthma Network (GAN) conducted a global survey among GAN centers. Data collection was between November 2020 and April 2021.

RESULTS

Fourteen GAN centers from 10 countries provided data on 169 children with asthma infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 was asymptomatic in 58 (34.3%), mild in 93 (55.0%), moderate in 14 (8.3%), and severe/critical in 4 (2.4%). Thirty-eight (22.5%) patients had exacerbation of asthma and 21 (12.4%) were hospitalized for a median of 7 days (interquartile range 3-16). Those who had moderate or more severe COVID-19 were significantly more likely to have exacerbation of asthma as compared to those who were asymptomatic or had mild COVID-19 (adjusted odds ratio (adjOR) 3.97, 95% CI 1.23-12.84). Those who used inhaled bronchodilators were significantly more likely to have a change of asthma medications (adjOR 2.39, 95% CI 1.02-5.63) compared to those who did not. Children who used inhaled corticosteroids (ICS) did not differ from those who did not use ICS with regard to being symptomatic, severity of COVID-19, asthma exacerbation, and hospitalization.

CONCLUSIONS

Over dependence on inhaled bronchodilator may be inappropriate. Use of ICS may be safe and should be continued in children with asthma during the pandemic of COVID-19.

Для цитирования: Chiang Chen-Yuan, Ellwood Philippa, Ellwood Eamon, García-Marcos Luis, Masekela Refiloe, Asher Innes, Badellino Héctor, Sanz Alberto Bercedo, Douros Konstantinos, El Sony Asma, Diaz Carlos González, Rodríguez Ms Albi, Moreno-Salvador Ana, Pérez-Martini Luis F, Filho Nelson Rosário, Shpakou Andrei, Sulaimanov Shairbek, Tavakol Marzieh, Valverde-Molina José, Yousef Abdullah A, Pearce Neil, GAN COVID Study Group. Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network.. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2021. DOI: 10.1111/pai.13709.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.